JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

Search

Evoke Pharma Inc

Închisă

4.51 -9.07

Rezumat

Modificarea prețului

24h

Curent

Minim

4.5

Maxim

4.96

Evoke Pharma Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

3 nov. 2025, 21:44 UTC

Câștiguri

Vertex Pharmaceuticals Revenue Climbs on Demand for Cystic Fibrosis Drugs

3 nov. 2025, 23:44 UTC

Market Talk

Nikkei May Rise on Weaker Yen, Hopes for Govt Econ Steps -- Market Talk

3 nov. 2025, 23:34 UTC

Market Talk

Gold Edges Lower Amid Lingering Worry Over China's Ending of Tax Incentive -- Market Talk

3 nov. 2025, 23:28 UTC

Câștiguri

Palantir Revenue Hits Another Record as Defense Work Booms -- 2nd Update

3 nov. 2025, 23:24 UTC

Câștiguri

Correct: Grab Holdings Sees FY2025 Adj Ebitda $490M-$500.0M, Higher Than $460M-$480M Projected in 2Q >GRAB

3 nov. 2025, 23:14 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Global Equities Roundup: Market Talk

3 nov. 2025, 23:14 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Deterra's Next CEO Might Bring New Approach to Deals -- Market Talk

3 nov. 2025, 23:12 UTC

Câștiguri

Grab Holdings Sees FY2025 Adj Ebitda $490-$500.0M, Higher Than $460M-$480M Projected in 2Q >GRAB

3 nov. 2025, 23:09 UTC

Câștiguri

Grab Holdings 3Q 2Q Adj EBITDA $136.0M Vs. $90.0M>GRAB

3 nov. 2025, 23:09 UTC

Câștiguri

Grab Holdings 3Q Net $17.0M Vs. Net $15.0M >GRAB

3 nov. 2025, 23:09 UTC

Câștiguri

Grab Holdings 3Q Rev $873.0M Vs. $716.0M >GRAB

3 nov. 2025, 23:06 UTC

Market Talk
Câștiguri

Palantir Execs Forecast Future of U.S. Workers In AI World -- Market Talk

3 nov. 2025, 22:36 UTC

Market Talk
Câștiguri

Palantir's U.S. Commercial Business Booms as It Expands AI -- Market Talk

3 nov. 2025, 22:31 UTC

Câștiguri

Franco-Nevada 3Q EPS $1.49 >FNV

3 nov. 2025, 22:31 UTC

Câștiguri

Franco-Nevada 3Q Rev $487.7M >FNV

3 nov. 2025, 22:24 UTC

Market Talk

Xero Bulls Expect Improving U.S. Momentum in 1H -- Market Talk

3 nov. 2025, 22:19 UTC

Achiziții, Fuziuni, Preluări

Starbucks Agrees to Sell Stake in China Business -- WSJ

3 nov. 2025, 21:59 UTC

Market Talk

RBA Set To Keep Rates On Hold; Remain Data Dependent -- Market Talk

3 nov. 2025, 21:54 UTC

Market Talk
Câștiguri

Westpac's Tech Challenge Keeps Jefferies Cautious -- Market Talk

3 nov. 2025, 21:54 UTC

Market Talk
Câștiguri

Global Equities Roundup: Market Talk

3 nov. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3 nov. 2025, 21:49 UTC

Câștiguri

Palantir Revenue Hits Another Record as Defense Work Booms -- Update

3 nov. 2025, 21:40 UTC

Câștiguri

Barry Diller's IAC Inks AI Deal With Microsoft. That Isn't Why the Stock Is Sliding. -- Barrons.com

3 nov. 2025, 21:31 UTC

Market Talk

Mexican Manufacturing Indexes Pick Up in October -- Market Talk

3 nov. 2025, 21:19 UTC

Câștiguri

Palantir Revenue Hits Another Record as Defense Work Booms -- WSJ

3 nov. 2025, 21:11 UTC

Achiziții, Fuziuni, Preluări

Pfizer Reports Earnings Tuesday. Management Has Big Questions to Answer. -- Barrons.com

3 nov. 2025, 21:11 UTC

Câștiguri

Diamondback Energy: Increasing Full Yr Oil Production Guidance to 495-498 MBO/d and Increasing Annual BOE Guidance to 910-920 MBOE/d >FANG

3 nov. 2025, 21:07 UTC

Câștiguri

Palantir Technologies: Raising 2025 U.S. Comml Rev Guidance to in Excess of $1.433B, Representing a Growth Rate of at Least 104% >PLTR

3 nov. 2025, 21:05 UTC

Câștiguri

Vertex Pharmaceutic Sees 2025 Rev $11.9B-$12B >VRTX

3 nov. 2025, 21:05 UTC

Câștiguri

Palantir Technologies 3Q Net $475.6M >PLTR

Comparație

Modificare preț

Evoke Pharma Inc Așteptări

Consens privind evaluarea

By TipRanks

0 ratings

0

Cumpărare

0

Păstrare

0

Vânzare

Date financiare

$

help-icon Live chat